To investigate the effects of statins and fibrates on CAC gene expression, HepG2 Dapagliflozin
were incubated for 24 h with various concentrations of two statins, simvastatin and fluvastatin, and two fibrates, WY-14643 and GW7647. After incubation, total mRNA was extracted and used to determine CAC transcript levels. As shown in Fig. 1A, the CAC mRNA level in HepG2 cells was increased by both statins and fibrates in a dose-dependent manner. Fluvastatin and GW7647, which were the most effective in increasing CAC mRNA in HepG2 cells, were also tested on rat hepatocytes (C9) and myocytes (L6.C11) at a concentration of 100 μM and 1 μM, respectively (Fig. 1B). 1 μM GW7647 caused a CAC mRNA increase of 3.5-, 1.6- and 2.3-fold in hepatocytes, myocytes and HepG2 cells, respectively; and 100 μM fluvastatin an increase of 3.9-, 3.3- and 3.2-fold in hepatocytes, myocytes and HepG2 cells, respectively. Finally, when GW7647 and fluvastatin were used in combination a synergistic effect was observed (Fig. 1B). These results clearly indicate anticodon
both statins and fibrates increase the CAC transcript level in primary and secondary cell lines.